Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 11 » default

Pharmacogenomics and Personalized Medicine


Archive: Volume 11, 2018

Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

Matevska-Geshkovska N, Staninova-Stojovska M, Kapedanovska-Nestorovska A, Petrushevska-Angelovska N, Panovski M, Grozdanovska B, Mitreski N, Dimovski A

Pharmacogenomics and Personalized Medicine 2018, 11:193-203

Published Date: 1 November 2018

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, van Schaik RHN

Pharmacogenomics and Personalized Medicine 2018, 11:179-191

Published Date: 24 October 2018

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Calderón-Ospina CA, Peña N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension

Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E

Pharmacogenomics and Personalized Medicine 2018, 11:157-165

Published Date: 20 September 2018

Qualitative user evaluation of a revised pharmacogenetic educational toolkit

Mills R, Haga SB

Pharmacogenomics and Personalized Medicine 2018, 11:139-146

Published Date: 4 September 2018

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA

Pharmacogenomics and Personalized Medicine 2018, 11:121-126

Published Date: 20 July 2018

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:113-119

Published Date: 29 June 2018

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2018, 11:107-112

Published Date: 18 June 2018

Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Emerging biomarkers in the diagnosis of prostate cancer

Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L

Pharmacogenomics and Personalized Medicine 2018, 11:83-94

Published Date: 16 May 2018

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation

Asleh R, Briasoulis A, Berinstein EM, Wiener JB, Palla M, Kushwaha SS, Levy AP

Pharmacogenomics and Personalized Medicine 2018, 11:71-82

Published Date: 23 April 2018

H3Africa: current perspectives

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, Ramsay M, Skelton M, Stein DJ

Pharmacogenomics and Personalized Medicine 2018, 11:59-66

Published Date: 10 April 2018

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Silvado CE, Terra VC, Twardowschy CA

Pharmacogenomics and Personalized Medicine 2018, 11:51-58

Published Date: 29 March 2018

Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

The utility of pharmacogenetic testing to support the treatment of bipolar disorder

Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C

Pharmacogenomics and Personalized Medicine 2018, 11:35-42

Published Date: 16 March 2018

The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2018, 11:1-5

Published Date: 28 December 2017